
Please try another search
For the three months ended 31 March 2022, Hookipa Pharma Inc revenues decreased 73% to $1.4M. Net loss increased 4% to $18M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing v increase of 16% to $4M (expense), R&D Expense - Government Grants decrease of 14% to $1.9M (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 1.45 | 3.9 | 3.87 | 5.38 |
Gross Profit | ||||
Operating Income | -20.15 | -22.05 | -21.17 | -19.29 |
Net Income | -17.97 | -21.23 | -20.04 | -17.15 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 195.71 | 126.05 | 142.17 | 166.16 |
Total Liabilities | 47.78 | 36.45 | 34.09 | 40.22 |
Total Equity | 147.93 | 89.59 | 108.09 | 125.93 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 0 Months |
Cash From Operating Activities | 1.73 | -66.02 | -52.77 | -35.13 |
Cash From Investing Activities | -1.83 | -12.58 | -7.44 | -4.95 |
Cash From Financing Activities | 75.29 | -0.23 | 0.17 | 0.19 |
Net Change in Cash | 74.89 | -76.27 | -60.48 | -40.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review